Safety, Efficacy, and Biomarker Results of a Phase 1b/2 Study Combining the CD40 Agonist Mitazalimab with mFOLFIRINOX in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC); Results of the OPTIMIZE-1 Trial
crossref(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要